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TObjective: Preexisting serum antibodies to heparin/platelet factor 4 complexes may
predispose adult cardiac surgical patients to increased perioperative morbidity and
mortality. We sought to determine the association between preoperative serum
antibodies directed against platelet factor 4/heparin complexes and major compli-
cations (in-hospital death or length of stay 10 days) in adult cardiac surgical
patients.
Methods: In a prospective observational study of 466 patients undergoing elective
coronary artery bypass grafting, valvular heart surgery, or both, preoperative serum
was assayed for anti–platelet factor 4/heparin antibody by using a commercially
available enzyme-linked immunosorbent assay (Asserachrom HPIA). Known pre-
operative risk factors were assessed, and patients were assigned a risk score by using
the validated method of Parsonnet and colleagues.
Results: Major complications (death or postoperative hospitalization 10 days)
occurred in 108 patients (23%). Overall, 59 (13%) patients had a positive preoper-
ative anti–platelet factor 4/heparin antibody screen (upper limit of normal is 0.5
optical density units). A positive assay result independently predicted an increased
risk of major complications (P  .0284; odds ratio, 1.98; 95% confidence interval,
1.06-3.62) over and above the effect of the Parsonnet risk score (P  .001; odds
ratio, 1.07; 95% confidence interval, 1.05-1.10). The level of preoperative anti–
platelet factor 4/heparin antibody was also significantly associated with major
complications (P  .036; odds ratio, 1.31; 95% confidence interval, 1.02-1.68)
independently of the Parsonnet risk score. No association (P .75) existed between
the Parsonnet risk score and preoperative anti–platelet factor 4/heparin antibody
level.
Conclusions: Serum antibodies directed against platelet factor 4/heparin complexes
are prevalent in the adult patient population undergoing cardiac surgery. The
presence of these antibodies before surgery is an independent predictor for death or
prolonged hospitalization after adult cardiac surgery.
More than 350,000 adult cardiac operations are performed in the UnitedStates annually. Although mortality rates are relatively low, perioperativecomplications remain common and include myocardial infarction, atrial
fibrillation, ventricular failure, and non–cardiac-related morbidities such as renal
dysfunction, gastrointestinal dysfunction, acute lung injury, stroke, and infections.
There is increasing recognition that many complications in cardiac surgical1,2 and
other critically ill patients3 may result from inflammatory or prothrombotic re-
sponses to tissue trauma. A possible prothrombotic trigger may result from the
development of serum antibodies directed against platelet factor 4 (PF4)/heparin
complexes.4 PF4/heparin complexes bound to platelet surfaces act as antibody
targets and lead to platelet activation with antibody binding. All adult cardiac
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CSPsurgical patients are exposed to heparin at the time of
cardiac catheterization or during the subsequent surgical
procedure itself. A substantial fraction of these patients have
antibodies directed against PF4/heparin complexes, and a
small subset progress to having heparin-induced thrombo-
cytopenia (HIT).5
HIT comprises a syndrome ranging from the asymptom-
atic presence of serum antibodies directed against PF4/
heparin complexes to isolated thrombocytopenia and, in the
most severe cases, thrombotic complications characterized
by venous and/or arterial thromboses that result in limb
amputations and death.6,7 In most published series to date,
antibodies to PF4/heparin complexes have been detected in
nearly one third of patients after cardiac surgery.8-12 Also,
although the incidence of clinically apparent HIT is low
(1%-3%), no large prospective investigations have assessed
the relationship between the preoperative presence of anti-
PF4/heparin antibodies and adverse outcomes after cardiac
surgery. Therefore, we tested the hypothesis that preexisting
serum antibodies directed against PF4/heparin complexes
are associated with in-hospital death or prolonged hospital-
ization after adult cardiac surgery.
Methods
Patient Selection
After institutional review board approval and informed consent,
patients undergoing coronary artery bypass grafting surgery, val-
vular heart surgery, or both, were enrolled in a prospective obser-
vational study at Duke University Medical Center in Durham,
North Carolina, and the Mount Sinai Medical Center in New York,
New York. Given the need for informed consent and the exclusion
of patients undergoing emergency operations, we could not enroll
consecutive patients.
Protocol
After benzodiazepine premedication, venous, radial arterial, and
central venous catheters were inserted. Induction and maintenance
of general anesthesia were accomplished with midazolam hydro-
chloride and fentanyl citrate infusions. Patients underwent stan-
dard nonpulsatile hypothermic (28°C-32°C) cardiopulmonary by-
pass with a membrane oxygenator. Porcine heparin sodium
Abbreviations and Acronyms
CI  confidence interval
ELISA enzyme-linked immunosorbent assay
HIT  heparin-induced thrombocytopenia
HIT(T) heparin-induced thrombocytopenia and
thrombosis
Ig  immunoglobulin
OD  optical density
OR  odds ratio
PF4  platelet factor 4(Elkins-Sinn, Inc, Cherry Hill, NJ) was administered as a load of
1568 The Journal of Thoracic and Cardiovascular Surgery ● Dec300 U/kg and supplemented as necessary to maintain an activated
clotting time of at least 450 seconds during cardiopulmonary
bypass. After cardiopulmonary bypass, heparin was neutralized
with protamine sulfate (Eli Lilly and Co, Indianapolis, Ind) ad-
ministered in a dose of 1 mg of protamine to 100 U of heparin.
Patients were managed after surgery according to standard insti-
tutional cardiac surgery “care maps” in which patients without
significant complications were discharged from the hospital on
postoperative day 4 or 5.
Blood samples for the determination of serum anti-PF4/heparin
antibody concentrations were obtained through an arterial catheter
immediately before the induction of general anesthesia; samples
were collected in glass tubes without additives and centrifuged for
10 minutes at 2000g. Plasma was stored at 70°C until assayed.
Levels of anti-PF4/heparin antibodies were measured by using a
commercially available enzyme-linked immunosorbent assay
(ELISA) according to the manufacturer’s instructions (Asserach-
rom HPIA; Diagnostica Stago, Parsippany, NJ), as described pre-
viously.13 In brief, antibodies bound to heparin/PF4 complexes on
the microtiter plate were measured by using a mixture of anti-
human immunoglobulin (Ig) G, IgM, and IgA. A positive antibody
screen was defined by the manufacturer as an absorbance value of
greater than 0.5 optical density (OD) units. All laboratory mea-
surements were performed on coded samples to blind investigators
to the patients’ identity and outcome.
Preoperative Risk Scoring and Definitions of
Patient Characteristics
Demographic information was collected before surgery, and a risk
score for mortality and morbidity was calculated according to the
previously validated Parsonnet risk scoring system.14,15 This sys-
tem sums assigned values for 19 factors known to increase mor-
tality and morbidity after cardiac surgery and generates a score
between 0 (ie, no risk factors) and 148; most patients in the
original series by Parsonnet and colleagues14 (n  4832) received
a score of 0 to 30, and approximately 50% of patients received a
score of 0 to 9.
Diabetes mellitus was considered present if a patient required
preoperative oral hypoglycemic or insulin medication. Myocardial
infarction was defined as electrocardiographic evidence of an old
myocardial infarction or previously documented episodes of increased
creatine kinase MB isoenzymes without concurrent electrocardio-
graphic changes. Hypertension was defined as blood pressure greater
than 140/90 mm Hg documented on at least 3 occasions or a
history of increased blood pressure requiring medication. A history
of congestive heart failure required at least 1 documented episode
of congestive heart failure diagnosed by using standard chest
radiograph examination, physical examination, and hemodynamic
criteria. A history of stroke was defined as the development of a
focal preoperative neurologic deficit. A history of atrial fibrillation
was defined as any previous episode of atrial fibrillation.
Outcomes
Postoperative length of stay was defined as the number of days
from the day of operation (day 0) to hospital discharge or death.
The major complication rate was the primary outcome of this study
and was defined as either in-hospital death or a postoperative
length of stay longer than 10 days in survivors. A recent retro-
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Pspective analysis of 2609 patients undergoing cardiac surgery at
Duke University Medical Center demonstrated that most patients
with a length of stay longer than 10 days experienced morbidity,16
so a prolonged length of stay (10 days) was selected as a
surrogate for the occurrence of significant medical complications.
All outcome measurements were performed by investigators
blinded to the patients’ laboratory data.
Statistical Analysis
Given an estimated incidence of 15% for the primary end point
(death or hospital length of stay 10 days), a sample size of at
least 400 subjects was expected to generate at least 60 events and
to allow for a stable logistic regression model to test our hypoth-
esis. The primary hypothesis was that increased preoperative con-
centrations of serum anti-PF4/heparin antibodies are associated
with death or prolonged hospitalization, as defined previously.
Unadjusted statistical analysis consisted of Pearson or Spear-
man correlation tests between continuous variables, Wilcoxon
2-sample rank sum tests for relating continuous variables with
response categories, and contingency table 2 tests for associations
between categorical variables. Adjusted statistical analysis used a
multivariable logistic regression model approach that modeled
response as a function of the preoperative serum anti-PF4/heparin
antibody result and the Parsonnet risk score. The antibody result
was categorized as normal or abnormal (an absorbance value0.5
OD units). The validated Parsonnet risk score was always included
in the different models to adjust for the effect of preoperative
patient comorbidities. This analysis tested the effects of preoper-
ative serum anti-PF4/heparin antibody and Parsonnet risk score
independently; each was adjusted for the information contributed by
the other. The assumption of linearity of fit in the logit model was
validated against nonlinear transformations and cubic spline fits.
We further tested the validity of the observed associations by
constructing a multivariable logistic model that included pre-
TABLE 1. Preoperative patient characteristics
Variable All patients Negativ
No. 466
Age (y) 67 11
Parsonnet risk score 12 8
Ejection fraction* 0.44 0.15
Preoperative hematocrit 0.38 0.05
Preoperative platelet count 215 70
Height (cm) 169 10
Weight (kg) 77 16
Body mass index (kg/m2) 27  5
History of diabetes 23%
Female sex 32%
Caucasian 75%
Not Caucasian 25%
Preoperative IV heparin 22%
Preoperative aspirin 56%
Data are presented as mean  SD as appropriate. Percentages are of the
measures) or Pearson 2 tests (categories) for group differences. PF4/hep
IV, intravenous. *Preoperative left ventricular ejection fraction. †Refers tooperative serum anti-PF4/heparin antibody level as a continu-
The Journal of Thoracicous variable (log transformed) along with the Parsonnet risk
score. In addition, we used univariate logistic regression to test
the association of the perioperative characteristics listed in Table
1 with major complications, adjusting for the Parsonnet risk score.
These factors included some variables represented in the preoper-
ative risk score (eg, age), as well as other known risk factors not
included (eg, height). Factors demonstrating a significant univar-
iate association (P  .05) with major complications were tested as
a block against the hypothesized model to determine whether they
would supplant the significance of the preoperative serum anti-
PF4/heparin antibody result. All statistical calculations and anal-
yses were performed by using the SAS software system (SAS
Institute Inc, Cary, NC).
Results
A total of 466 patients were enrolled. Preoperative demo-
graphics and intraoperative characteristics for the study
population are presented in Table 1. Of note, only race and
height were statistically significantly different between
those with increased versus normal antibody assay results.
Preoperative serum anti-PF4/heparin antibody levels
ranged from 0.02 to 3.11 OD units, with a mean of 0.29
(SD, 0.37; median, 0.17). The Parsonnet preoperative risk
score ranged from 0 to 41, with a mean of 11.9 (SD, 8.4;
median, 11). Overall, major complication occurred in 108
patients (23.2%), as summarized in Table 2. In-hospital
death occurred in 23 patients (4.9%), and 96 patients
(20.6%) had a postoperative hospital length of stay longer
than 10 days. A total of 85 patients (18.2%) remained
hospitalized for longer than 10 days and survived to dis-
charge. Overall, the postoperative length of stay ranged
from 0 to 180 days, with a mean of 12.0 days (SD, 18.1
4/heparin <0.5 Positive: PF4/heparin >0.5 P value
(87%) 59 (13%)
 11 65 12 .2228
 8 12 8 .9971
 0.15 0.41  0.17 .2214
 0.05 0.37  0.05 .2414
 72 214  58 .572
 9 165  11 .0124
 16 75 17 .3975
 5 28 7 .6735
3% 22% .9999
1% 37% .3696
6% 63% .0262†
4% 37%
3% 17% .3207
6% 54% .8888
ie, all 466 patients. P values are from Wilcoxon rank sum tests (continuous
Preoperative serum anti–platelet factor 4/heparin immunoglobulin G level;
parison for race.e: PF
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12
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2
3
7
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2
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total,
arin,days; median, 7 days). Among survivors, the length of stay
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CSPranged from 3 to 108 days, with a mean of 10.9 days (SD,
13.8 days; median, 7 days). The hospital length of stay
was statistically significantly longer in patients with an
increased antibody result (Table 2). Deaths were associated
with the following potential etiologies: sepsis/multisystem
organ failure (n  8), ventricular failure/cardiogenic shock
(n  7), stroke/coma (n  3), ischemic bowel (n  2),
sudden death/unknown (n  2), and ventricular arrhythmia
(n  1).
The relationship of Parsonnet risk score with preopera-
tive serum anti-PF4/heparin antibody levels was not signif-
icant (P  .75). Figure 1 presents the percentage of patients
with a major complication by preoperative serum anti-PF4/
heparin antibody level. Of note, death or prolonged hospi-
talization occurred in 33.9% of patients with a positive
preoperative serum anti-PF4/heparin antibody result. In
TABLE 2. Intraoperative and postoperative patient charact
Variable All patients
No. 466
CABG only 72%
Valve only 24%
CABG and valve* 4%
CPB duration (min) 129 44
No. of distal bypass grafts 3.0 1.7
Units of pRBCs within 48 h 1.1 1.9
Units of platelets within 48 h 0.8 3.1
Units of FFP within 48 h 0.3 1.0
Any blood product within 48 h 41%
Postoperative ICU length of stay (d) 3.0 4.2
Postoperative hospital length of stay (d) 12.0 18.1
Data are presented as mean  SD as appropriate. Percentages presente
test (continuous measures) or the Pearson 2 test (categories) for grou
immunoglobulin G level; CABG, coronary artery bypass graft surgery; CPB
frozen plasma; ICU, intensive care unit. *Valve repair or replacement sur
Figure 1. Major complication rate and mean Parsonnet risk score
by preoperative serum anti-heparin/PF4 antibody result.
1570 The Journal of Thoracic and Cardiovascular Surgery ● Deccontrast, 21.6% of patients with a negative assay result
experienced a major complication. This difference in out-
come is not explained by the Parsonnet index of known
preoperative risk factors, because Parsonnet scores (mean
SD) were almost identical in groups with a positive versus
negative assay result (11.8  8.0 vs 11.9  8.4; P  .89;
Figure 1). The logistic regression models described below
help us to understand the relationships depicted in Figure 1.
We first tested our specific hypothesis with a multivari-
able logistic regression model that included the preoperative
serum anti-PF4/heparin antibody category and the Parson-
net risk score. In this model, a positive preoperative serum
anti-PF4/heparin antibody result independently predicted an
increased risk for major complications (P  .0284; odds ratio
[OR], 1.98; 95% confidence interval [CI], 1.06-3.62) over and
above the effect of Parsonnet risk score (P  .001; OR, 1.07;
95% CI, 1.05-1.10). The overall model 2 for covariates (like-
lihood ratio test) was 32.88 with 2 df (P .001). There was no
significant interaction between the preoperative serum anti-
PF4/heparin antibody result and the Parsonnet risk score.
To define further the validity of this model, we tested the
effect of the preoperative serum anti-PF4/heparin antibody
level as a continuous rather than a categorical variable. In
this logistic regression model, the preoperative serum anti-
PF4/heparin antibody level was again independently asso-
ciated with an increased risk of major complications (P 
.036; OR, 1.31; 95% CI, 1.02-1.68) over and above the
effect of Parsonnet risk score (P  .001; OR, 1.07; 95% CI,
1.05-1.10). The overall model 2 for covariates was 32.7
with 2 df (P  .0001).
Three of the potential predictors from the list in Table 1
showed significant associations with major complications in
separate models after adjustment for Parsonnet risk score:
ics
tive: PF4/heparin <0.5 Positive: PF4/heparin >0.5 P value
407 (87%) 59 (13%)
72% 70% .8983†
24% 27%
4% 3%
129 44 130  46 .8819
3.0 1.7 3.2  1.6 .3037
1.1 1.9 1.3  1.9 .4153
0.6 2.4 1.9  5.7 .1627
0.3 1.0 0.4  1.1 .3957
40% 44% .5732
3.0 4.1 3.4  5.3 .0776
11.9 18.3 12.9 17.3 .0284
of the total, ie, all 466 patients. P values are from the Wilcoxon rank sum
erences. PF4/heparin, Preoperative serum anti–platelet factor 4/heparin
diopulmonary bypass; pRBC, allogenic packed red blood cells; FFP, fresh
†Refers to 3-group comparison for procedure type.erist
Nega
d are
p diff
, carage (P  .0511), ejection fraction (P  .0050), and preop-
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Perative hematocrit (P  .0432). (Age was marginally sig-
nificant as an additional factor, even though it is represented
in the Parsonnet risk score as well.) None of these 3 pre-
dictors was significantly different between the 2 antibody
result groups (Table 1). When added to the model by using
the binary antibody result (normal vs abnormal) and Par-
sonnet risk score, these 3 covariates reduced the significance
of the preoperative serum anti-PF4/heparin antibody result
(P  .0889). However, the addition of these 3 covariates to
the model by using the antibody result as a continuous
variable and the Parsonnet risk score did not supplant the
significance of preoperative serum anti-PF4/heparin anti-
body levels (P  .0383).
Some investigators have characterized the anti-PF4/hep-
arin antibodies assayed with the ELISA we used into 3
categories: positive (0.5 OD units), intermediate (0.25-0.5
OD units), and negative (0.25 OD units).10 For purposes
of comparison with these data, we assessed the anti-PF4/
heparin antibodies by using a similar approach (Figure 2).
Inclusion of these 3 categories of antibody, instead of the
2-category approach described previously, into multivariate
analyses with Parsonnet risk score still resulted in signifi-
cance of preoperative serum anti-PF4/heparin antibody lev-
els (P  .0349) as a predictor for death or prolonged
hospitalization.
Discussion
This report represents the largest descriptive prospective
investigation evaluating the association between preopera-
tive anti-PF4/heparin antibodies and death or prolonged
hospitalization after cardiac surgery. We have demonstrated
that preoperative anti-PF4/heparin antibodies are associated
with adverse outcomes after cardiac surgery and may ac-
Figure 2. Major complication and mean Parsonnet risk score by
preoperative serum anti-heparin/PF4 antibody result.count for a significant proportion of the variability in out-
The Journal of Thoraciccome previously reported among patients with seemingly
identical preoperative risk factors.
Several prospective studies have assessed the incidence
of HIT after cardiac surgery.9,12,17 Few studies have re-
ported the prevalence of anti-PF4/heparin antibodies before
cardiac surgery. The prevalence of anti-heparin/PF4 anti-
bodies identified in our investigation, 13%, is consistent
with that in previously published reports.10,11 For example,
Bauer and colleagues10 measured anti-PF4/heparin antibod-
ies by ELISA before surgery and 5 days after surgery in 111
patients undergoing cardiac surgery with cardiopulmonary
bypass. The observed prevalence of anti-heparin/PF4 anti-
bodies was 51% after surgery versus 19% before surgery.
Bauer and colleagues’ study was not powered adequately to
assess for the relationship between antibodies and adverse
outcome. Indeed, the only outcome assessed was thrombo-
sis. In contrast, our study assessed a more general metric
of complications. Several additional similarities between
these 2 studies’ results are evident. In both studies, non-
Caucasians were more likely to have a positive antibody
assay. In addition, both studies observed a lower prevalence
of anti-PF4/heparin antibodies in patients who received
heparin immediately before surgery. The clinical relevance
and mechanisms underlying these findings remain unclear.
The selection of our primary end point merits discussion.
Prior investigations related to anti-PF4/heparin antibodies
have focused on overt manifestations of HIT, namely,
thrombocytopenia, thrombosis, or both—serious but rela-
tively infrequent sequelae of cardiac surgery. Because we
did not focus on HIT as an outcome, it was not rigorously
assessed. Instead, our investigation assessed the association
between preexisting anti-PF4/heparin antibodies and a broader
measure of morbidity, ie, death or prolonged hospitaliza-
tion. By the nature of its observational design, our investi-
gation cannot define the mechanism by which heparin/PF4
antibody complexes might contribute to postoperative mor-
bidity, mortality, or both. Nevertheless, several lines of evi-
dence suggest that the associations we report are not spurious.
Our overall results are consistent with a recent study by
Williams and associates18 that involved 218 patients with
acute coronary syndromes. In their study, patients with
anti-PF4/heparin antibodies were more likely to die (30.4%
vs 11.3%; P  .011) or experience myocardial infarction
(21.7% vs 6.2%; P  .008). This study by Williams and
associates, in conjunction with our findings, suggests a role
for anti-PF4/heparin antibodies in predicting or causing
adverse outcomes not classically viewed as being associated
with HIT(T).
A limitation of this investigation is that anti-PF4/heparin
antibodies may not be mechanistically involved in postop-
erative morbidity and mortality but may merely represent a
surrogate marker for sicker patients at greater risk for ad-
verse outcomes. In an attempt to minimize this confounder,
and Cardiovascular Surgery ● Volume 130, Number 6 1571
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a previously validated preoperative risk scoring system, the
Parsonnet score, to adjust for patient-specific preoperative
risk. The fact that preoperative measurement of anti-
heparin/PF4 antibodies independently predicted increased
risk for in-hospital death or prolonged hospitalization sup-
ports the potential clinical relevance of these antibodies.
Nevertheless, on the basis of our data, we cannot recom-
mend at this time that physicians routinely test for anti-PF4/
heparin antibodies before cardiac surgery.
The mechanism(s) that could account for the adverse
effects of the PF4/heparin antibodies will require further
investigation. However, recent studies have demonstrated
that platelets are activated by the binding of the PF4/heparin
antibodies and that the FcR receptor plays a role in trig-
gering the activation response.19,20 Platelets alone or in
combination with leukocytes, fibrin, and other inflammatory
substances could disrupt vascular function and impair post-
operative recovery. The PF4/heparin antibodies can bind to
endothelial cells and trigger venous and arterial thrombosis
and alter organ function. Clearly, a host of factors—some
genetic and others environmental—are likely to contribute
to the clinical outcome in patients with these antibodies.
Because these antibodies are associated with adverse out-
comes, future studies should investigate whether alternative
forms of intraoperative and postoperative anticoagulation,
antiplatelet therapy, or both, could be beneficial. There may
be a need to develop additional approaches to manage
high-risk patients who have increased anti-PF4/heparin
antibodies.
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